Navigation Links
New Protein Inhibitor Halts Growth Of Cancerous Cells

Researchers reporting their findings in the current Biology online on February 8, have developed a small-molecule inhibitor of a protein that plays// key roles in the control of cell division. The researchers show that the inhibitor can halt the growth of tumors in mice and cancer-derived cells growing in culture.

The findings are reported in companion papers reported by two collaborating groups—one (Lenart et al.) led by Jan-Michael Peters of the Research Institute of Molecular Pathology in Vienna, and the other (Steegmaier et al.) led by Norbert Kraut of Boehringer Ingelheim Austria GmbH.

Because cancer cells are typically fast growing and can mutate to adapt to new growth conditions, effective drug-based therapies will likely succeed in part by impeding multiple functions required for cell division and survival. One particular class of proteins, known as kinases, is known to play especially critical roles in the division of healthy cells, and appears to also be important for cell division in cancer cells, even though these cells are diseased and have lost some of the restraints on division that normal cells impose on themselves.

Because central aspects of cell division are under the control of just a few key kinases, these proteins represent potentially important targets for new cancer therapeutics, but few if any effective inhibitors have been identified as acting specifically and effectively against one particular cell-division kinase, known as Plk1.

In the new work, Steegmaier et al. isolated a chemical compound, which they term BI 2536, that they demonstrate to be a potent inhibitor of Plk1, and show that BI 2536 can indeed effectively halt the growth of cancerous cells, both in cell culture and in an animal model for human tumor growth. BI 2536 caused growth arrest and cell death in cell lines derived from a variety of human cancers, and it inhibited the growth of human tumor grafts in mice, resulting in the
'"/>




Page: 1 2

Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
3. Unravelling the secrets of ‘Huntingtin’ Protein - towards the treatment of ‘Huntingtons’ Disase
4. Unravelling the secrets of ‘Huntingtin’ Protein - towards the treatment of Huntingtins’ Disese
5. Protein in urine foresees heart disease
6. Levels Of Blood Proteins May Help Heart Disease Care
7. Protein signals need for heart surgery
8. Protein and fat improve memory
9. Clotting Protein plays a role in nerve repair
10. High Levels of Protein Linked to Brain Shrinkage
11. Protein can change worn muscle fibres
Post Your Comments:
(Date:10/8/2008)... Dr. Paul Parker is pleased to announce enha...computer imaging for http://www.parkercenter.net/...oplasty in New Jersey]. Paramus plastic surgeon, ...raw attention to itself but rather complement othe...ll appearance, gender and ethnicity." , ...
(Date:10/8/2008)... Gastorenterologist Dr. Patricia Raymond off... East Longmeadow, MA (PRWEB) Octob...sary. In fact, the average person passes gas about...three liters daily). However, every body behaves d...s. If you are one of those unlucky few, follow the...
(Date:10/8/2008)... AccurateAnswers™ support program prov...r http://www.appointment-plus.com [online schedu... Scottsdale, AZ (PRWEB) October 8, 2008 -- Appoi...duling software, continues to expand its software ...t "software as a service" providers are ...
(Date:10/7/2008)... Merck KGaA (EMD in North America) announced...iance with Nano-Terra, Inc., a leading nanotechnol... DARMSTADT, Germany (Business Wire EON) Octob...companies, announced in February 2007, was to deve...solutions based on Merck,s materials. , , , After ...
Breaking Medicine News(10 mins):Health News:New Jersey Rhinoplasty Patients Can Now See the Future at The Parker Center for Plastic Surgery New Jersey 2Health News:New Jersey Rhinoplasty Patients Can Now See the Future at The Parker Center for Plastic Surgery New Jersey 3Health News:New Jersey Rhinoplasty Patients Can Now See the Future at The Parker Center for Plastic Surgery New Jersey 4Health News:Managing Gas Isn't Rocket Science 2Health News:Managing Gas Isn't Rocket Science 3Health News:Appointment-Plus Continues Innovation With Technical Support Program 2Health News: Merck KGaA and Nano-Terra Announce Extension of Nanotechnology Solutions Alliance 2Health News: Merck KGaA and Nano-Terra Announce Extension of Nanotechnology Solutions Alliance 3
...a study published in the August issue of Neurology...ents are admitted to and discharged from the hospi...icantly. Studies have shown that several treatment...ount of disability, complications and the risk of ...
...a recent study researchers say that they found tha...te tumour cells in laboratory settings. Scientist...state cancer // could be due to a rapid increase i... the western diet in recent years. Omega-6 fats ha...
...shown that the efficacy of low-carb diets could be...chers question whether raising protein intake coul...esearchers set out to test the hypothesis that inc...bohydrate intake decreases the appetite, leads to ...
...he century started with a big bang, bringing hope ...ever, fate and nature had ideas of their own. 20...isasters and man made ones. The first internatio... February 1st in California when a jet bound for S...
Other Medicine News:Health News:Simple Procedural Improvements Can Improve Care Of Stroke Patients 2Health News:Finding The Key To Weight Loss! 2Health News:SARS (Bird Flu) spreading in the Asian continent 2
(Date:10/7/2008)... VIENNA, Va., Oct. 7 /...y that it has entered into a Material Transfer,Agr...h Clinical Center,(NIHCC) and the laboratory of Dr... molecular basis of changes to the tumor microenvi... Dr. Marincola is the Chief of,the Infectious Dise...
(Date:10/7/2008)... - Data Presented Today at ACG Annual Sc...wire-FirstCall/ -- Ironwood,Pharmaceuticals, Inc. ...,Inc. (NYSE: FRX ) today announced the presentati...clotide,s safety and efficacy in 420 patients with...). Analysis of the data,indicates that once- daily...
(Date:10/7/2008)... Several abstracts highlighting CIMZIA,s long...hn,s disease patients presented at American Colleg... /- Data from two studies,p...of Gastroenterology,(ACG) Annual Meeting demonstra...PEGylated anti-TNF alpha (Tumor Necrosis Factor al...
(Date:10/7/2008)... - Planned 15 Patient Cohort Enrolled in Stage A...ombination With Carboplatin and Paclitaxel -, TUS...grine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a cl...monoclonal antibodies for the treatment of cancer ...nced that it has completed,enrollment in the first...
Breaking Medicine Technology:CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4Doctors See How Cancer Drug Can Damage Kidneys 14210 1Doctors See How Cancer Drug Can Damage Kidneys 14210 2Doctors See How Cancer Drug Can Damage Kidneys 14210 3New Tools Boost Alzheimers Awareness 14206 1New Tools Boost Alzheimers Awareness 14206 2New Tools Boost Alzheimers Awareness 14206 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 1WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 4WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 5WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 6WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 7WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 8WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 9WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 10WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 11WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 12The Makers of Conquer HA 28TM 29 Launch All Natural Double Strength Anti Inflammatory Formula 14200 1The Makers of Conquer HA 28TM 29 Launch All Natural Double Strength Anti Inflammatory Formula 14200 2
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: